Americord Announces Increasing Stem Cell Yields, Including Record Collection

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­NEW YORK, June 1, 2016 /PRNewswire/ -- Americord, the fastest growing cordblood bank in the country and a leader in the advancement of umbilical cord blood, cord tissue, and placenta tissue banking, announced today that it has reached several milestones, including record cord blood collection volumes and record yields of total nucleated cell (TNC) counts.

Logo - http://photos.prnewswire.com/prnh/20160526/372831LOGO

Using Cord Blood 2.0™, the company recorded its highest cord blood collection volume since launching the proprietary process in October 2014. This breakthrough in cord blood banking ensures that the maximum number of stem cells are preserved for storage and available for the families who need them.

Cord Blood 2.0 collected a record volume of 183 ml, more than triple the industry average cord blood collection volume of 60 ml. While average yields can treat patients weighing up to 65 lbs., Cord Blood 2.0 collections extend treatment to adults weighing up to 165 lbs.

In addition to collection volume, TNC counts are also an important measure of application potential for stored cells. The company recently achieved a record TNC yield of 2 billion, considerably surpassing the industry benchmark of 470 million.

"At Americord, our mission is to improve lives by bringing innovative technologies to cord blood and tissue banking." commented Martin Smithmyer, Americord Founder and CEO, "While cord blood collection volumes vary, our standard collection using Cord Blood 2.0 often yields up to twice the industry average."

With over 354 clinical trials currently exploring the potential uses for stem cell therapy, Americord is committed to providing more treatment options to a greater number of patients with advancements in new collection and processing methods like Cord Blood 2.0.

About Americord Registry

Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry's website at http://www.americordblood.com for more information.

Press contact: Hannah Touby | [email protected] | 866­-503-­6005

SOURCE Americord Registry

Related Links

http://cordadvantage.com